ClinicalTrials.gg
CompletedNCT06588517Updated Sep 19, 2024

Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions

A Phase 1 interventional study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Idiopathic Pulmonary Fibrosis, sponsored by Overseas Pharmaceuticals, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Overseas Pharmaceuticals, Ltd. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 6 months ago, and no results have been posted to the registry.
  • Registered 4 months after the study started (first participant enrolled Apr 2024, registered Sep 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Enrollment
54th of 60
12 · median 83
Started
2024
with 7 others
Phase 1
20 of 67
5 open now
Registered
42nd of 67
by date
Lead sponsor
3 of 67
Overseas Pharmaceuticals, Ltd.

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 54th largest by enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2024, is one of 20 in phase 1, and was the 42nd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

A Randomized, Open-Label, Two-Period, Double-Crossover Comparative Study on the Pharmacokinetics of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Chinese Subjects under Fed Conditions Primary objective: To evaluate the bioequivalence of test product and reference product by comparing their plasma concentrations and main PK parameters by oral administration in healthy Chinese subjects under fed conditions using Pirfenidone Modified-Release Tablets (strength: 600 mg/tablet) developed by Overseas Pharmaceuticals, Ltd. as the test product and Pirfenidone Tablets (trade name: Pirespa®, strength: 200 mg/tablet) produced by Shionogi \& Co., Ltd. as the reference product. Secondary objective: To evaluate the safety of Pirfenidone Modified-Release Tablets (test product) and Pirfenidone Tablets (reference product) after oral administration in healthy Chinese subjects under fed conditions.

Read the detailed description

It is designed to be a single-center, randomized, open-label, two-period, double-crossover trial. All subjects must sign an informed consent form (ICF) prior to participation in the trial. Twenty-four (24) eligible healthy subjects (male and female, with an appropriate sex ratio) screened through physical examination from D-14 to D-1 of dosing will be randomized into Group T-R and Group R-T, with 12 subjects in each group. The enrolled subjects will be admitted to phase I ward of the clinical study site 1 day before medication in each period and fasted for more than 10 h before medication.

On the morning of medication, after the collection of blank blood samples within 60 minutes before administration, both group will have a standard breakfast that completed within 10 min±30 s. Group T will orally take 1 tablet of Pirfenidone Modified-Release Tablets (600 mg/tablet, Overseas Pharmaceuticals, Ltd.) developed by Overseas Pharmaceuticals, Ltd. in 12 minutes after starting a standard breakfast ; Group R will orally take 3 tablet of Pirfenidone Modified-Release Tablets (600 mg/tablet, Overseas Pharmaceuticals, Ltd.) under fed condition(The first tablet should be taken in 12 minutes after the start of a standard breakfast, the second tablet should be taken in 30 minutes (±30 s) after the start of a standard lunch, and the third tablet should be taken in 30 minutes (±30 s) after the start of a standard dinner).

Standard lunch is served 4 h after administration, standard dinner 10 h later, water is prohibited before and within 1 h after administration (except 240 mL water for medication), and unified diet is required during the trial.

Unified diet is required during the trial. The trial method in period II is the same as that in period I, with a washout period of 6 days.

PK blood sampling and blood sample processing:

Cubital venous blood will be collected at 31 time points: before administration (0 h) and 0.25 h, 0.50 h, 1.00 h, 1.50 h, 2.00 h, 3.00 h, 4.00 h, 4.50 h, 5.00 h, 6.00 h, 7.00 h, 7.50 h, 8.00 h, 9.00 h, 10.00 h, 10.25 h, 10.50 h, 11.00 h, 11.50 h, 12.00 h, 12.50 h, 13.00 h, 14.00 h, 16.00 h, 18.00 h, 20.00 h, 24.00 h, 28.00 h, 36.00 h and 48.00 h after administration of each period.

Four milliliters (4 mL) (scale of 4 mL should be pre-marked on the blood collection tube) will be drawn and placed in a labeled EDTA-2K anticoagulant tube. The collection, processing and storage procedures of biological samples are subject to the final sample operation manual. Sitting vital signs (including respiratory rate, body temperature, pulse rate, and sitting blood pressure) will be measured within 1 h before administration and at 2 ± 0.5 h, 8 ± 0.5 h, 24 ± 0.5 h and 48 ± 1 h after administration. Subjects should receive physical examination, vital signs, ECG, and laboratory-related tests on D2 after the last dose. The subjective feelings of subjects as well as possible adverse reactions (ARs) and adverse events (AEs) occurred during the trial should be observed and inquired. All subjects will be followed up for 7 days after the end of the last dose to inquire the occurrence of any subsequent AEs. If occurred, AEs should be recorded and followed up. An AE emerged during the trial should be followed up until it is resolved.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Pirfenidone
  • Modified-Release
  • Idiopathic pulmonary fibrosis
  • Healthy Volunteers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects over the age of 18 years (including those aged 18 years), with an appropriate sex ratio;
  2. Male subjects with a body weight ≥ 50.0 kg, and female subjects with a body weight ≥ 45.0 kg; (BMI = body weight (kg)/[height (m)]2) within the range of 19-26.0 kg/m2 (including the critical value);
  3. Subjects with good health conditions, no medical history in respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, and mental system;
  4. Subjects (including partners) who have no plans of pregnancy and voluntarily take appropriate measures from the date of signing the (14 days before signing the informed consent for female subjects) to 6 months after the end of the study;
  5. Subjects who are able to communicate well with the investigator and understand and adhere to the study requirements. Subjects who fully understand the objective, nature, method and possible ARs of the trial, voluntarily act as subjects, and sign the ICF before any study procedures are started;

Exclusion criteria

Exclusion Criteria:

  1. Patients with an allergic history to the study drug or its (such as lactose), or an allergic history to drug, food , pollen or a specific allergic history (asthma, allergic rhinitis, eczema);
  2. Patients with a history of photosensitivity and existing skin irritation symptoms such as rash and pruritus;
  3. Subjects who have special dietary requirements and cannot accept a unified diet;
  4. Subjects with a history of dysphagia or any gastrointestinal disorder affecting drug absorption;
  5. Subjects who cannot tolerate venipuncture and have a history of fear of needles and hemophobia;
  6. Subjects with hematological, endocrine, cardiovascular, hepatic, renal and pulmonary disorders that may affect drug absorption, distribution, metabolism and excretion;
  7. Subjects with a surgical history or taking the study drug or participating in other drug clinical trials within 3 months prior to the study;
  8. Subjects with blood donation or massive blood loss (\> 450 mL) within 3 months before the study;
  9. Subjects taking special diet (including pitaya or grapefruit and products containing grapefruit ingredients) or having strenuous exercise within 7 days before taking the study drug, or having other factors affecting drug absorption, distribution, metabolism and excretion;
  10. Subjects administered with any prescription drugs, over-the-counter, herbal, or health products within 14 days prior to taking the study drug;
  11. Regular drinkers within 6 months prior to the study, i.e., drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirit containing 40% alcohol or 150 mL of wine);
  12. Subjects smoking more than 5 cigarettes per day in the first 3 months of the study; Or positive results of tobacco test;
  13. Subjects who have consumed chocolate, any caffeine-containing, or xanthine-rich food or beverage, such as coffee, strong tea, and cola 48 h before taking the study drug;
  14. Subjects having taken any alcohol-containing products within 48 h before taking the study drug, or having a positive result for alcohol screening;
  15. Female subjects with positive pregnancy
  16. Subjects positive for , -Ab, anti- or primary syphilis screening;
  17. Subjects positive for drug screening or with a history of drug abuse within the past five years or using drugs 3 months before the trial;
  18. Subjects with underlying medical, psychiatric, psychological or other discomfort conditions, poor compliance, or who, as judged by the investigator, are not suitable for the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Group T

    take the tablet under fed condition ,1 tablet at a time, once a day.Test product (T): Pirfenidone Modified- Release Tablets Strength: 600 mg/tablet Batch No.: 08532 Content: 600 mg/tablet Valid to: January/2025 Storage Conditions: sealed at normal temperature (10-30°C) Manufacturer: Overseas Pharmaceuticals, Ltd.

    Drug: Pirfenidone Modified-Release Tablets

  • Active comparator
    Group R

    take the tablet under fed condition ,1 tablet at a time, three times a day.Reference product (R): Pirfenidone Tablets Strength: 200 mg/tablet Batch No.: 0239 Content: 200 mg/tablet Valid to: September 2026 Storage Conditions: sealed at room temperature Manufacturer: Shionogi \& Co., Ltd..

    Drug: Pirfenidone Tablets

Interventions

  • DrugPirfenidone Modified-Release Tablets

    take the tablet under fed condition, 1 tablet at a time, once a day.

  • ake the tablet under fed condition, 1 tablet at a time, three times a day.

06

What researchers measure

Primary outcomes

  1. Area under the curve from time zero to the time of the last quantifiable plasma concentration of the period (AUC0-last)

    The 90% CI for the geometric mean ratios (i.e., antilog-transformation for 90% CI of difference with log transformation) of AUC0-last within \[0.8, 1.25\] range will be used to determine the result of bioequivalence.

    Time frame: 1 month

  2. Area under the curve from time zero to infinity (AUC0-inf)

    The 90% CI for the geometric mean ratios (i.e., antilog-transformation for 90% CI of difference with log transformation)of AUC0-inf within \[0.8, 1.25\] range will be used to determine the result of bioequivalence.

    Time frame: 1 month

Secondary outcomes

  1. Peak concentration at each treatment period (Cmax,tp)

    The 90% CI for the geometric mean ratios (i.e., antilog-transformation for 90% CI of difference with log transformation)of Cmax,tp within \[0.8, 1.25\] range will be used to determine the result of bioequivalence.

    Time frame: 1 month

  2. Peak concentration of the first dosing (Cmax)

    Individual pirfenidone and 5-carboxyl-pirfenidone plasma concentration-time profile for each treatment period will be established.

    Time frame: 1 month

  3. Time to reach peak concentration of the first dosing (Tmax)

    Individual pirfenidone and 5-carboxyl-pirfenidone plasma concentration-time profile for each treatment period will be established.

    Time frame: 1 month

  4. Terminal half-life (T1/2)

    Individual pirfenidone and 5-carboxyl-pirfenidone plasma concentration-time profile for each treatment period will be established.

    Time frame: 1 month

  5. Elimination rate constant (λz)

    The PK parameters of each subject were calculated for statistical analysis

    Time frame: 1 month

  6. Apparent clearance(CL/F)

    The PK parameters of each subject were calculated for statistical analysis

    Time frame: 1 month

  7. Apparent volume of distribution(Vd/F)

    The PK parameters of each subject were calculated for statistical analysis

    Time frame: 1 month

07

Study locations

1 site
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Apr 2024, 0 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 0 months is below that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2024
First posted
Sep 19, 2024
StartActual
Apr 8, 2024
Primary completionActual
Apr 19, 2024
CompletionActual
Apr 27, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06588517
Lead sponsor
Overseas Pharmaceuticals, Ltd.
Collaborators
Shanghai ShouYan Clinical Development Co.,Ltd.
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Apr 8, 2024
Primary completion
Apr 19, 2024
Completion
Apr 27, 2024
Last update
Sep 19, 2024

Study contacts

Cao Yu, Doctor
principal investigator · The Affiliated Hospital of Qingdao University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion